The VERITY Steering Committee

Slides:



Advertisements
Similar presentations
Review Article Acute Pulmonary Embolism
Advertisements

Diagnosing venous thromboembolism – protocols and problems, the Salford experience Kerstin Hogg Clinical Lecturer, University of Manchester.
Venous Thrombo-embolism In Pregnancy
Venous thromboembolic diseases: Deep vein thrombosis
Venous thromboembolic diseases: Pulmonary embolism
VTE Toolkit Chapter Five Venous Disease Coalition
Atiya Khalid GPST1 A & E;AGH. Defination: DVT is the formation of a thrombus (blood clot) in a deep vein, usually in the legs, which partially or completely.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Derivation and Validation of a Prediction Tool for Venous Thromboembolism (VTE): A VERITY Registry Study Roopen Arya, Shankaranarayana Paneesha, Aidan.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose,
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Low-molecular-weight heparin (LMWH) use in an oncological setting Emma Lowe, Melanie Lowe, Hilary Oldham, Joan Karasu. Clinical service technicians, Pharmacy.
Annual Report 2003 Power Point Presentation. Mechanics of merging data.
Jomo Osborne Lung-2015 Baltimore, USA July , 2015.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Clinical predictors of adverse outcome in VTE outpatients – the VERITY PUSH (Prospective Follow-Up Survey in Verity Hospitals) study Peter Rose, Aidan.
Risk Assessment for VTE. Which of the following best describes you?
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing June 2012 NICE clinical guideline.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.
Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.
Pulmonary Embolism in Patients with Unexplained Exacerbation of COPD: Prevalence and Risk Factors Isabelle Tillie-Leblond, MD, PhD; Charles-Hugo Marquette,
Diagnosis Recitation. The Dilemma At the conclusion of my “diagnosis” presentation during the recent IAPA meeting, a gentleman from the audience asked.
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
ELIGIBILITY CRITERIA- Summarised
Ahmed Mohamed Abd Elmajeed 99
AJ Wagstaff, SJ Goodyear, IK Nyamekye Worcestershire Royal Hospital.
CRT 2012 Venous Disease.
Venous Thromboembolism Prophylaxis (VTE)
Diagnosis of venous thromboembolism
By: Dr. Nalaka Gunawansa
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Thromboprophylaxis after Hip Replacement Surgery
Clinical Knowledge Summaries CKS Pulmonary embolism (PE)
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
D-dimer and helical CT-PA based diagnostic algorithm for PE
Assessing the uptake of national initiatives
Deep vein thrombosis outpatient pathway and ultrasound sensitivity
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
Copyright © 2012 American Medical Association. All rights reserved.
Ortho Warfarin Dosing Protocol
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
Waleed Alselwi1, Thomas Coventary2, Faisal Azam1
Pulmonary Thrombo-Embolism
Update on the Diagnosis and Management of CTEPH in Latin America
Confirmed VTE Treatment Pathway
The Utilization of Sequential Compression Devices Among Pregnant Women
OBMC Core Measures January 2015
Six stage journey When diagnosed with a brain tumour.
Pharmacovigilance (PV)
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Succinct Review of the New VTE Prevention and Management Guidelines
Lessons on Thrombosis and Thromboembolism
Pulmonary Embolism /Pulmonary hypertension
Managing Pulmonary Embolism Posthospital Discharge
Calculate Well’s score for PE (BOX1)
Identifying Low-Risk Patients with Pulmonary Embolism Suitable For Outpatient Treatment A VERITY Registry Pilot Study N Scriven, T Farren, S Bacon, T.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Preventing Venous Thromboembolism Participating Hospital Survey
Principal recommendations
Presentation transcript:

The VERITY Steering Committee Third Venous Thromboembolism Registry Report 2005

Schematic of the report production process

List of contributors

List of contributors

List of contributors

Example table

Number of risk factors for patients with VTE (n=4,603)

Overview

Database overview

The growth of the database (n=27,179)

Data submitted by each centre

Number of risk factors and diagnosis

Number of risk factors for patients with VTE (n=4,603)

Final diagnosis and the number of risk factors (n=17,175)

Age distribution for all patients with VTE (n=27,123)

Final diagnosis over time (n=21,486)

Age and gender for patients with VTE

Age and gender for patients with VTE (n=6,045)

Age and gender for patients with VTE and Cancer (n=799)

Rates of different risk factors in patients who have VTE

Presence of various risk factors and final diagnosis

Task Force of the British Committee for Standards in Haematology13

D-dimer result and final diagnosis

Final diagnosis and D-dimer test (n=16,005)

D-dimer result, DVT pre-test probability and final diagnosis

Final diagnosis, D-dimer result, D-dimer test and DVT pre-test probability (n=11,585)

Suitability for home treatment1 amongst patients with confirmed DVT (n=5,371)

Reason patients with DVT were deemed unsuitable for home treatment; (patients unsuitable for home treatment with recorded reason n=466)

Duration of LMWH therapy and time to therapeutic INR in patients with DVT; patients receiving both treatments only (n=3,248)

Kaplan-Meier survival curves for patients with confirmed diagnosis of DVT and PE (n=2,224)

Pulmonary embolism

Primary and final diagnosis

Numbers of risk factors

Number of risk factors according to final diagnosis (n=4,603)

Different risk factors

Presence of selected risk factors for PE and non-PE patients

Age and disease

Age distributions according to final diagnosis (n=6,115)

A. Management of suspected non-massive pulmonary A. Management of suspected non-massive pulmonary embolism with isotope lung scanning off site only

B. Management of suspected non-massive pulmonary B. Management of suspected non-massive pulmonary embolism with isotope lung scanning available on site

PTP score and final diagnosis

PTP score distributions for patients with confirmed PE and non-PE patients (n=279 and n=342 respectively)

PTP score distributions for patients with confirmed PE and non-PE patients (n=279 and n=342 respectively)

PTP score D-dimer and final diagnosis

Using <4 and ≥4 to classify the PE PTP score Final diagnosis, D-dimer results and PE PTP score for patients with a suspected PE (n=438) Using <4 and ≥4 to classify the PE PTP score

Using <2,2-6 and >6 to classify the PE PTP score Final diagnosis, D-dimer results and PE PTP score for patients with a suspected PE (n=438) Using <2,2-6 and >6 to classify the PE PTP score

Other investigations performed

Investigations performed and diagnosis

Chest x-ray

The Royal Perth Hospital algorithm

Treatment of patients with PE – location of treatment

Suitability of PE patients for home treatment1 (n=457)

Doses of LMWH

Average number of doses of LMWH for non-PE and PE patients; bars denote standard error

Prediction of the risk of adverse events in PE patients

Thromboprophylaxis

Source of referral for medical inpatients with VTE

Source of referral for surgical inpatients with VTE

Source of referral for patients with a history of surgical inpatient stay and VTE (n=685)

Final diagnosis and inpatient history - Overview

Final diagnosis and inpatient history

Focus on medical inpatient history

Medical inpatient history for each final diagnosis (n=21,080)

Focus on surgical inpatient history

Surgical inpatient history for each final diagnosis (n=20,996)

Speciality for VTE patients who have recently had surgery (n=685)

Thromboprophylaxis provision for VTE patients (n=3,189)

Source of referral and the use of thromboptophylaxis for VTE patients (n=3,580)

Trends in the use of LMWH as thromboprophylasis for VTE patients (n=730)

Thromboprophylaxis and surgical speciality for VTE patients

Thromboprophylaxis provision and surgical speciality for VTE patients (n=603)

Thromboprophylaxis and inpatient stay

Type of thromboprophylaxis, final diagnosis and inpatient history

Thromboprophylaxis and risk factors in medical inpatients with VTE

Final diagnosis and new risk score

Final diagnosis of VTE and weighted risk score (n=5,692)

Thromboprophylaxis and the weighted score

Thromboprophylaxis and weighted risk score (n=4,794)

Kaplan-Meier survival curves for patients with confirmed diagnoses of DVT according to recent medical inpatient history (n=242 and n=1,883 respectively)

Kaplan-Meier survival curves for patients with confirmed diagnoses of DVT according to recent surgical inpatient history (n=266 and n=1,839 respectively)

Number of referrals over time according to patients’ history and Percentage of patients with confirmed VTE over time according to patients’ history

Number of referrals over time according to patients’ history and Percentage of patients with confirmed VTE over time according to patients’ history

VTE and Cancer

Cancer rates amongst VTE patients at each hospital

Final diagnosis and cancer

Presence of a final diagnosis of VTE in cancer and non-cancer patients

Cancer, age and gender in patients with VTE

Cancer rates broken down by age and gender for patients with VTE (n=5,655)

Specific type of cancer and age for patients with VTE

Specific type of cancer and age for patients with VTE

Cancer rates broken down by age for the most frequently occuring cancers in VERITY amongst patients with VTE (n=5,582)

Specific type of cancer and final diagnosis

Type of cancer and final diagnosis (n=1,205)

D-dimer and cancer

D-dimer results in the context of cancer (n=15,240)

Location of treatment

Location of treatment and cancer for VTE patients (n=5,480)

Doses of LMWH

Duration of LMWH therapy and time to therapeutic INR in patients with DVT in the context of cancer; patients receiving both therapies only (n=3,444)

Duration of LMWH therapy in patients with VTE in the context of cancer (n=4,138)

Kaplan-Meier survival curves for patients with confirmed diagnoses of VTE according to the presence of absence of cancer (n=2,224)

Walsgrave hospital: Cancer and medium-term mortality in VTE patients

VTE and Pregnancy

Final diagnosis and pregnancy

Final diagnosis and pregnancy (n=12,336)

Risk factors and pregnancy

Final diagnosis and pregnancy (n=3,389)

Final diagnosis and selected risk factors amongst pregnant patients

Investigations and pregnancy

Investigations in pregnant patients

Treatment and pregnancy – use of LMWH

LMWH use and final diagnosis for pregnant patients (n=378)

Doses of LMWH

LMWH doses and final diagnosis for pregnant patients; bars denote standard errors (n=89 and 50 respectively)

Warfarin therapy and post partum

Warfarin use and final diagnosis for post partum patients (n=425)

Summary of protocol for thromboprophylaxis in women with previous VTE and / or thrombophiliai

A clinical model for predicting pre-test probability for deep vein thrombosisi

Variables used to determine a pre-test probability score in patients with suspected pulmonary embolismii

A new weighted score to determine the risk of VTEiii